Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 4782 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 
Table of Contents
LETTER TO THE EDITOR
Year : 2013  |  Volume : 17  |  Issue : 6  |  Page : 1133-1135

Pragmatic use of metformin in pregnancy based on biopsychosocial model of health


1 Department of Obstetrics and Gynaecology, Bharti Hospital, Karnal, Haryana, India
2 Department of Medicine, Government Medical College and Hospital, Chandigarh, India

Date of Web Publication3-Dec-2013

Correspondence Address:
Bharti Kalra
Department of Obstetrics and Gynaecology, Bharti Hospital, Kunjpura Road, Karnal 132 001, Haryana
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.122654

Rights and Permissions

How to cite this article:
Kalra B, Gupta Y. Pragmatic use of metformin in pregnancy based on biopsychosocial model of health. Indian J Endocr Metab 2013;17:1133-5

How to cite this URL:
Kalra B, Gupta Y. Pragmatic use of metformin in pregnancy based on biopsychosocial model of health. Indian J Endocr Metab [serial online] 2013 [cited 2020 Feb 24];17:1133-5. Available from: http://www.ijem.in/text.asp?2013/17/6/1133/122654

Sir,

We have read with interest various articles on gestational diabetes mellitus (GDM), published in IJEM. [1],[2],[3] We observe controversy regarding not only screening, but also management of GDM. This is especially true regarding use of oral anti-diabetic agents (OAAs). The initial focus for achieving glycemic control uses life-style modifications. By altering diet and exercise, up to 90% of patients with GDM will achieve target blood glucose levels. [3] For several years, human insulin has been the only treatment option for diabetes that could not be controlled by diet and life-style modifications alone. [3] Insulin has proven efficacy and safety. Over the last 15 years, randomized controlled trials (RCTs) and meta-analysis of these RCTs comparing OAAs (metformin and glyburide) with insulin have shown equivalent safety and efficacy both for maternal and fetal health outcomes. [4] The results are still short-term, but safety data from RCT for off springs followed until 2 years of age is encouraging. [5] The long-term effects are still unknown, resulting in cautious use of OAAs in pregnancy. This caution is justified with the current level of evidence.

The economic burden of GDM management is an issue which has not been addressed adequately. In resource challenged societies like India, the cost of treatment of GDM with insulin is many fold higher (10 fold in a study by Rai et al.) as compared with metformin. [6] Thus, OAAs may become through financial necessity, a preferred treatment in developing countries. This rationale is supported by the fact that use of insulin for GDM (which may comprise as few as 3-6 weeks of treatment), requires labor-intensive teaching and monitoring. Injection of insulin at multiple times in the day may be inconvenient. Hypoglycemia and weight gain are other feared risks. There is also the bitter truth of gender discrimination in health-care, observed in many communities across the world, especially in South Asia. [7] The diagnosis of GDM adds to stress at an individual as well as family level. While this burden is not avoidable, the added stress of having to take injectable therapy is perceived as social stigma by many women and families. Because of all these sempiternal factors, there is a need to objectively assess the possible role of OAAs, especially metformin, in GDM.

In view of similar efficacy of metformin (pregnancy category B drug) and insulin in women with GDM (RCTs based results), selected women with GDM may be candidates for OAAs. We propose a pragmatic, individualized approach to use of metformin in mild GDM [Table 1], based on the biopsychosocial model of health. [8] Mild GDM is defined as an abnormal result on an oral glucose-tolerance test but a fasting glucose level below 95 mg/dl. [9]
Table 1: Pragmatic use of metformin in mild GDM$, based on biopsychosocial health model

Click here to view


A multinational study in regions with high prevalence of GDM, including India, will provide valuable evidence and guidance in this regard. This will help in individualizing therapy appropriately, rather than generalizing results of trials to all populations. Hence, we feel that there is a need for a large RCT to compare metformin with insulin in GDM patients keeping biopsychosocial indications in mind. The evidence gathered from such a trial will provide answers to many questions and may help in taking care of the health-care burden, psychological stress and social stigma in future. Whether such a study, focusing on a cheap, non-patented, "non-profitable" molecule such as metformin, will find sponsors is an altogether different and yet unanswered, question!

 
   References Top

1.Magon N. Gestational diabetes mellitus: Get, set, go from diabetes capital of the world to diabetes care capital of the world. Indian J Endocrinol Metab 2011;15:161-9.  Back to cited text no. 1
    
2.Kalra S, Malik S, John M. Gestational diabetes mellitus: A window of opportunity. Indian J Endocrinol Metab 2011;15:149-51.  Back to cited text no. 2
    
3.Magon N, Seshiah V. Gestational diabetes mellitus: Non-insulin management. Indian J Endocrinol Metab 2011;15:284-93.  Back to cited text no. 3
    
4.Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemic agents vs insulin in management of gestational diabetes: A systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:457.e1-9.  Back to cited text no. 4
    
5.Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: The offspring follow-up (MiG TOFU): Body composition at 2 years of age. Diabetes Care 2011;34:2279-84.  Back to cited text no. 5
    
6.Rai L, Meenakshi D, Kamath A. Metformin: A convenient alternative to insulin for Indian women with diabetes in pregnancy. Indian J Med Sci 2009;63:491-7.  Back to cited text no. 6
    
7.Bajaj S, Jawad F, Islam N, Mahtab H, Bhattarai J, Shrestha D, et al. South Asian women with diabetes: Psychosocial challenges and management: Consensus statement. Indian J Endocrinol Metab 2013;17:548-62.  Back to cited text no. 7
    
8.Engel GL. The need for a new medical model: A challenge for biomedicine. Science 1977;196:129-36.  Back to cited text no. 8
    
9.Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009;361:1339-48.  Back to cited text no. 9
    



 
 
    Tables

  [Table 1]


This article has been cited by
1 Metformin use in gestational diabetes mellitus
Yashdeep Gupta,Rajiv Singla,Sanjay Kalra
Diabetes Research and Clinical Practice. 2014;
[Pubmed] | [DOI]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References
    Article Tables

 Article Access Statistics
    Viewed863    
    Printed11    
    Emailed0    
    PDF Downloaded259    
    Comments [Add]    
    Cited by others 1    

Recommend this journal